Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001363661 | SCV001559782 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2023-11-03 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with threonine, which is neutral and polar, at codon 158 of the BRCA2 protein (p.Ser158Thr). This variant is present in population databases (rs113114005, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with BRCA2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1055054). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA2 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002341770 | SCV002639102 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-04-12 | criteria provided, single submitter | clinical testing | The p.S158T variant (also known as c.472T>A), located in coding exon 4 of the BRCA2 gene, results from a T to A substitution at nucleotide position 472. The serine at codon 158 is replaced by threonine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |